Oslo, 16 May 2017 - Please find enclosed the financial report and presentation
for first quarter 2017.
Highlights
fimaChem
- Presentation of the Phase I data at The International Liver Congress and the
Annual Meeting of the US Cholangiocarcinoma Foundation- Interaction with authorities to determine fastest way to market
- Preparing for repeated treatments in Phase II through an extension of Phase
I
fimaVacc
- Progressing the Phase I study in healthy volunteers for clinical validation
of the vaccination technology- Awarded up to NOK 14.3 million from the Norwegian Research Council for
further development of the vaccination platform
Corporate
- Completed the fully underwritten rights issue of NOK 70 million
CEO, Per Walday, comments:
"The emerging interim Phase I data in bile duct cancer presented at the
International Liver Congress supports our regulatory interactions to determine
the fastest way to market for fimaChem. It is still early days, but we have
promising signs of effect and survival from Phase I in this orphan indication.
The completed fully underwritten rights issue of NOK 70 million enables PCI
Biotech to strengthen the fimaChem asset through a Phase I extension, to explore
safety of repeated treatments in parallel with the preparations for Phase II.
The near-term focus for the company is to get regulatory clarity on the
requirements for a marketing authorisation for fimaporfin in bile duct cancer,
initiate the Phase I extension and to complete the clinical translation of the
promising preclinical results with fimaVacc".
PCI Biotech Q1 2017 Presentation.pdf
PCI Biotech Q1 2017 Report.pdf
Presentation Slide 12 - Phase I Extension Study - har dette vært meldt tidligere?
